CIRM Funded Clinical Trials

Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

Disease Area:
Epilepsy, Genetic Disorder
Investigator:
Institution:
CIRM Grant:
CLIN2-18731 (Pre-Active)
Award Value:
$15,000,000.00
Trial Sponsor:
Encoded Therapeutics
Trial Stage:
Phase 2
Trial Status:
Launching
Targeted Enrollment:
N/A